Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,056 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study.
Tasaki Y, Hamamoto S, Yamashita S, Furukawa J, Fujita K, Tomida R, Miyake M, Ito N, Iwamoto H, Mimura Y, Sugiyama Y, Unno R, Okada A, Yasui T, Furukawa-Hibi Y. Tasaki Y, et al. Among authors: okada a. Front Immunol. 2025 Jan 9;15:1483956. doi: 10.3389/fimmu.2024.1483956. eCollection 2024. Front Immunol. 2025. PMID: 39850887 Free PMC article.
Usefulness of four-dimensional noise reduction filtering using a similarity algorithm in low-dose dynamic computed tomography for the evaluation of breast cancer: a preliminary study.
Uraoka D, Matsuda M, Tanabe Y, Kawaguchi N, Nishiyama C, Okada A, Uda K, Suekuni H, Nishiyama H, Kamei Y, Kurata M, Kitazawa R, Nakano S, Kido T. Uraoka D, et al. Among authors: okada a. Jpn J Radiol. 2025 Jan 24. doi: 10.1007/s11604-024-01730-0. Online ahead of print. Jpn J Radiol. 2025. PMID: 39849240
Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial.
Kaneda H, Daga H, Okada A, Nakatani Y, Tani Y, Oka T, Sawa K, Sakai K, Nishio K, Kawaguchi T. Kaneda H, et al. Among authors: okada a. Invest New Drugs. 2025 Jan 23. doi: 10.1007/s10637-025-01505-y. Online ahead of print. Invest New Drugs. 2025. PMID: 39847172
2,056 results